Article

Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer

2007-01-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ed97c59b-caed-5d25-92b7-c0754a6a6d02
DOI: 10.1097/01243894-200701000-00006

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung CancerDOI 10.1097/01243894-200701000-00006Read

EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib: extension of an emerging paradigm.Semantic proximity Read

Role of epidermal growth factor receptor mutations in predicting sensitivity or resistance to targeted agents in non-small-cell lung cancer.Semantic proximity Read

Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinibSemantic proximity Read

Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.Semantic proximity Read

Development and validation of a multivariable predictive model for EGFR gene mutation status in patients with lung adenocarcinoma.Semantic proximity Read

Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.Semantic proximity Read

Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations.Semantic proximity Read

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.Semantic proximity Read

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.Semantic proximity Read

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.Semantic proximity Read

Update on epidermal growth factor receptor mutations in non-small cell lung cancer.Semantic proximity Read

Predictive factors for response and for resistance to tyrosine kinase inhibitor therapy in lung cancer.Semantic proximity Read